{"schema_version":"secwatch.filing_event.v1","accession":"0000944809-23-000015","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.670404+00:00","generated_at":"2026-06-18T09:12:36.164534+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO subsidiary ModeX licenses EBV vaccine to Merck for $50M upfront, up to $872.5M milestones","bullets":["ModeX grants Merck exclusive worldwide license for MDX-2201, a preclinical nanoparticle vaccine targeting EBV.","OPKO receives $50M upfront; eligible for up to $872.5M in development and commercial milestones.","Tiered royalties from high single digits to low double digits on global sales of the vaccine product.","Joint research program until IND filing; Merck to lead clinical development and commercialization thereafter.","A portion of payments may be payable to Sanofi under ModeX's prior in-license agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000944809-23-000015","json":"https://secwatch.observer/filing/0000944809-23-000015.json","markdown":"https://secwatch.observer/filing/0000944809-23-000015.md","text":"https://secwatch.observer/filing/0000944809-23-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000094480923000015/0000944809-23-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000094480923000015/opk-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:12:36.164534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd3ca471ead6cfc045be47ba9d7367fd53eb228e","claim":"OPKO HEALTH, INC. entered into License and Research Collaboration Agreement with Merck Sharp & Dohme LLC valued at $50 million initial payment, up to $872.5 million milestones, tiered royalties high single digits to (effective 2023-03-08).","evidence_excerpt":"On March 8, 2023, ModeX Therapeutics, Inc. (“ ModeX ”), a wholly-owned subsidiary of OPKO Health, Inc. (“ OPKO ”), OPKO with respect to certain sections, and Merck Sharp & Dohme LLC (“ Merck ”) entered into a License and Research Collaboration Agreement (the “ Agreement ”) pursuant to which Merck obtained from ModeX a license to certain patent rights and know-how of ModeX.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000094480923000015/0000944809-23-000015-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Merck Sharp & Dohme LLC"},{"label":"Value","value":"$50 million initial payment, up to $872.5 million milestones, tiered royalties high single digits to"},{"label":"Effective","value":"2023-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}